Shelter Cat URI Management Protocol: FHV-1, FCV, and Stress-Driven Disease

Why URI Is the Most Common Shelter Cat Disease

Upper respiratory infection (URI) in shelter cats is so prevalent that it is functionally inevitable in any cat population housed above a few dozen. Feline herpesvirus type 1 (FHV-1) is present in roughly eighty percent of cats in shelter populations; feline calicivirus (FCV) in roughly thirty percent. Add in Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma species, and the practical operational question is not whether your cats will develop URI but how badly and how often. A reliable shelter cat URI management protocol mitigates the inevitable.

The Association of Shelter Veterinarians (ASV), UC Davis Koret Shelter Medicine Program, and the American Association of Feline Practitioners (AAFP) all publish protocols. The unifying insight is that URI in shelter cats is a stress-driven disease as much as an infectious one; reducing the stress load reduces the URI load.

The Pathogen Mix

Feline herpesvirus-1 is the dominant viral player. Like all herpesviruses, FHV-1 establishes lifelong latency after primary infection and reactivates under stress, intermittently shedding from clinically normal carriers. The feline herpesvirus and feline herpesvirus 1 overview pillars cover the disease. Cat eye herpes covers the ocular component (FHV-1 is a leading cause of feline keratitis and corneal ulceration).

Feline calicivirus presents with oral ulceration and pneumonia in addition to nasal-ocular signs. Some virulent systemic disease (VSD) strains have caused outbreaks with high mortality; see feline calicivirus for the clinical framing. Bordetella bronchiseptica and Chlamydia felis are bacterial co-pathogens that complicate viral URI; Mycoplasma is increasingly recognized as a primary or co-pathogen in chronic-conjunctivitis presentations.

Stress as a Driver, Capacity for Care as the Lever

Stress is the operational lever that distinguishes a low-URI shelter from a high-URI one. Crowding, novel environment, handler turnover, dog-noise, missing hiding spaces, inconsistent feeding schedules, and forced sociability all elevate cortisol and depress immune function. FHV-1 latent virus reactivates predictably under these conditions. Mycoplasma and Chlamydia emerge under similar pressure.

Capacity for care (CfC) is the framing intervention. Shelters that hold their cat population at or below capacity, provide hide-boxes or perches in every kennel, separate from dog wards by sound and visual barrier, maintain consistent care schedules, and use cat-friendly handling (AAFP Feline-Friendly Handling Guidelines) experience materially less URI. Cite ASV CfC framework, UC Davis Koret CfC tools, and University of Florida Maddie’s program research. See cat upper respiratory infection for the species pillar.

Cat-Friendly Handling and Environmental Enrichment

Cat-friendly handling protocols (AAFP-aligned) reduce stress-driven URI recrudescence. The principles: minimize restraint, allow the cat to exit the carrier on her own, work at the cat’s pace, use food and toys as desensitization, never extract a cat by scruffing, never tower over a fearful cat. Trained staff and volunteers using these techniques produce measurably lower stress scores in shelter cats.

Environmental enrichment reduces baseline stress: hide-boxes (a covered space within every kennel where the cat can be unseen), elevated perches, scratching surfaces, food puzzles, novel toys rotated. The cat environmental enrichment protocols and mental enrichment for cats pillars cover the framework. A cat with a hiding spot displays measurably less stress behavior than one without.

Vaccination Doesn’t Sterilize, But Protects Against Severity

The FVRCP vaccine (feline viral rhinotracheitis, calicivirus, panleukopenia) reduces the severity of clinical disease but does not produce sterilizing immunity against FHV-1 or FCV carriage. Vaccinated cats can still become infected, latently carry, and shed; the vaccine reduces the clinical severity of disease, not its presence. This is a critical operational distinction.

The shelter vaccination on intake protocol covers the intake FVRCP framework. The Chlamydia felis vaccine is added in shelters with documented chlamydial conjunctivitis; see chlamydia vaccine cats. The bordetella vaccine decision covers the cat-side Bordetella vaccination (less common than canine, considered case-by-case).

Treatment: Supportive Care First

Most URI cases resolve with supportive care alone: rest, food (warmed canned food for cats with nasal congestion who cannot smell their kibble), hydration, gentle nasal cleaning with saline, and time. Stress reduction is therapy. The shelter-medicine veterinarian doses any medication by species, weight, condition, and product; this article names the framework, not numbers.

Famciclovir (see famciclovir for cats) is used for FHV-1 flares with documented efficacy in published studies (Drazenovich et al. 2009 was an early controlled efficacy study; subsequent work has refined the framework). It is the antiviral most used in shelter context for severe FHV-1 disease. L-lysine for cats has historically been used for FHV-1 management; recent reviews have debated the efficacy and some have suggested neutral-to-harmful effects in shelter populations. The shelter-medicine veterinarian weighs the evidence on the lysine question; many programs have removed lysine from standing-orders protocols in light of the recent literature.

Antibiotic Use for Bacterial Co-Infection

Bacterial co-infection (Bordetella, Chlamydia, Mycoplasma, secondary bacterial overgrowth on viral-damaged respiratory epithelium) is common in moderate and severe URI. Antibiotic selection targets the suspected organism. Doxycycline for cats is broadly effective against Chlamydia, Mycoplasma, and Bordetella; it is a common first-line choice in shelter URI requiring antibiotic therapy. Azithromycin is a second-line option where doxycycline cannot be used.

Antibiotic stewardship matters; not every URI case needs antibiotics. Mild viral URI without evidence of bacterial co-infection (no purulent discharge, no fever, no pneumonia signs) is treated with supportive care alone. The shelter-medicine veterinarian sets the standing-orders criteria for antibiotic escalation; over-treatment selects for resistance and adds cost without improving outcomes.

Isolation for Severe and Suspect-Novel-Strain Cases

Mild and moderate URI cases are typically managed in their housing with stress reduction, supportive care, and monitored recovery. Severe cases (refractory to outpatient management, pneumonia signs, sepsis risk) move to the isolation ward (see shelter isolation ward setup). Suspect-novel-strain cases (calicivirus VSD presentation: high fever, edema, jaundice, severe systemic illness) move to isolation regardless of severity-rating, because the strain identification matters and the operational risk is severe.

Within isolation, URI cases are sub-zoned away from parvovirus or panleukopenia cases; the cross-contamination between cohorts is operationally significant. PPE discipline applies.

Adoption Disclosure: Carriers, Flares, and What to Tell Adopters

The honest disclosure to adopters of a cat with documented URI history (which, in shelter context, is nearly all cats): FHV-1 is lifelong latent and may flare under stress, particularly in the first weeks of adoption when the cat is acclimating to a new environment. Most flares are mild and self-limiting; a small percentage become recurrent or chronic.

The adopting a cat with herpes virus and adopting a cat with chronic sneezing pillars cover the adopter-facing framing. The adopting a cat with feline calicivirus covers the FCV-specific disclosure. Honest disclosure reduces returns and builds trust.

Outbreak Scenarios: Calicivirus VSD

The serious URI outbreak scenario is virulent systemic disease (VSD) calicivirus. VSD-FCV strains have been documented in multiple US shelter outbreaks since the early 2000s, with mortality rates of thirty to fifty percent and rapid spread. The presentation differs from typical URI: high fever, facial and limb edema, jaundice, hemorrhage, multi-organ failure.

VSD-FCV response is an outbreak event: stop intake, isolate, vaccinate the unaffected cohort with FVRCP (provides cross-protection against most FCV strains but not all), depopulate the environment with peroxymonosulfate (FCV is non-enveloped and shares the disinfectant-resistance profile of parvo and panleuk), consult the shelter-medicine veterinarian for strain typing and exposure tracing. The outbreak response parallels the panleukopenia outbreak protocol in operational structure.

The Kennel-Cough Counterpart in Cats

Cats can develop Bordetella bronchiseptica infection that resembles canine kennel cough, particularly in multi-species housing situations. The dog kennel cough, kennel cough in dogs, dog kennel cough treatment, and kennel cough home treatment pillars cover the canine framing; the cat-side Bordetella case is managed with similar antibiotic and supportive-care logic. Cross-species spread between shelter dogs and cats has been documented in shared-air-handling buildings.

Frequently Asked Questions

Will vaccinating cats prevent URI in our shelter?

It will reduce the severity, not eliminate the presence. FVRCP vaccine is not sterilizing against FHV-1 or FCV. Reducing stress through capacity for care, hide-boxes, cat-friendly handling, and environmental enrichment reduces URI more than any single vaccine intervention.

Is L-lysine still recommended?

Recent literature has raised concerns about efficacy and possible harm in shelter populations. Many shelter-medicine programs have removed lysine from standing-orders protocols; others continue cautious case-by-case use. The shelter-medicine veterinarian makes the call for your facility.

How do we tell an adopter their cat has FHV-1?

Honestly. Most cats from any shelter carry FHV-1 latently; flares are stress-driven and usually mild. Provide written information (cross-link the herpesvirus and chronic-sneezing adopter pillars) and connect the adopter to their primary-care veterinarian for any recurrent cases.

When does URI require isolation versus in-place management?

Severe disease (refractory to supportive care, pneumonia signs, systemic illness, suspected VSD-FCV) isolates. Mild and moderate cases without systemic signs are managed in place with stress reduction, supportive care, and the operational expectation of self-limited recovery in seven to fourteen days.

What’s the most underappreciated lever in URI management?

Hide-boxes in every kennel. A simple covered cardboard box or commercial hiding apparatus reduces measurable stress scores and downstream URI flares. The cost is trivial; the impact is documented in shelter-medicine literature.